• Follow
  • Follow
  • Follow
  • About
    • About
    • Management Team
    • Board of Directors
  • Our Businesses
    • Active Ingredients (Ceapro)
    • Oral Thin Film (Nualtis)
  • Technologies
  • Investors and News
    • Press Releases
    • Events & Presentations
    • Investor Contacts
    • Stock Information
    • Financial Filings
      • SEC Filings
      • SEDAR
    • Governance
      • Corporate Governance
      • Board Committees
      • Board Diversity Matrix
      • Clawback Policy
      • Annual Reports
    • Email Alerts
  • Contact

Aeterna Zentaris Announces Completion of Patient Recruitment in Dose-Finding Pediatric Study of Macimorelin

by jtcir-auto | Jan 28, 2020 | Press Releases

– Study P01 is the first of two studies as agreed with the EMA in the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic — Study P01 final study results expected in Q2 2020 -CHARLESTON, S.C., Jan. 28,...

Aeterna Zentaris Announces Completion of Patient Recruitment in Dose-Finding Pediatric Study of Macimorelin

by jtcir-auto | Jan 28, 2020 | Press Releases

– Study P01 is the first of two studies as agreed with the EMA in the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic — Study P01 final study results expected in Q2 2020 -CHARLESTON, S.C., Jan. 28,...

Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement for Continued Listing

by jtcir-auto | Jan 27, 2020 | Press Releases

CHARLESTON, S.C., Jan. 27, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical therapies, today...

Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement for Continued Listing

by jtcir-auto | Jan 27, 2020 | Press Releases

CHARLESTON, S.C., Jan. 27, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical therapies, today...

Aeterna Zentaris Receives NASDAQ Notification Regarding Minimum Bid Price Requirement

by jtcir-auto | Jan 8, 2020 | Press Releases

CHARLESTON, S.C., Jan. 08, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today announced that it has received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the closing bid...

Aeterna Zentaris Receives NASDAQ Notification Regarding Minimum Bid Price Requirement

by jtcir-auto | Jan 8, 2020 | Press Releases

CHARLESTON, S.C., Jan. 08, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today announced that it has received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the closing bid...
Next Entries »

Recent Posts

  • COSCIENS Biopharma Inc. Reports Q3 2026 Results and Provides Update On Convertible Debenture Offering
  • COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS COMPLETES SECOND TRANCHE OF CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS ACQUIRES NUALTIS CORP.
  • COSCIENS Biopharma Inc. Reports Q2 2026 Results

Recent Comments

No comments to show.
Latest News:

Stock Info

TSX:

 

 

Sign Up For Alerts

Click Here and Stay Up To Date With Cosciens News and Events

 

Contact Us

© 2026 COSCIENS BIOPHARMA   All Rights Reserved   Terms and Conditions  Privacy Policy

  • Follow
  • Follow
  • Follow